



## Pædiatric Rheumatology InterNational Trials Organisation

Genoa, December 18, 2016

### ADVISORY COUNCIL

#### CHAIRMAN

Alberto Martini, MD, Prof  
Genova, Italy  
Tel: +39-010-38-28-54  
albertomartini@gaslini.org

#### Counsellors

Tadej Avcin, MD, PhD  
Ljubljana, Slovenia  
tadej.avcin@kclj.si

Michael Beresford, MBChB  
Liverpool, United Kingdom  
m.w.beresford@liverpool.ac.uk

Susan Nielsen, MD  
Copenhagen, Denmark  
rh04430@rh.dk

Pierre Quartier, MD  
Paris, France  
pierre.quartier@aphp.fr

Claudia Saad Magalhaes, MD, PhD  
Botucatu, Brazil  
claudi@fmb.unesp.br

Nico Wulfraat, associate professor  
Utrecht, Netherlands  
n.wulfraat@umcutrecht.nl

#### SENIOR SCIENTIST

Nicola Ruperto, MD, MPH  
Genova, Italy  
Tel: +39-010-38-28-54  
nicolaruperto@gaslini.org

To the attention of:

**Ivan Foeldvari**

Hamburg Centre for Pediatric and Adolescent Rheumatology  
Competence Centre for Uveitis and scleroderma in childhood and adolescence  
Dehnhaid 120 D-22081, Hamburg  
Germany  
foeldvari@t-online.de

Object: certificate of PRINTO enrollment

With the present we certify that

**Ivan Foeldvari**

Hamburg Centre for Pediatric and Adolescent Rheumatology, Competence  
Centre for Uveitis and scleroderma in childhood and adolescence  
Dehnhaid 120, D-22081 Hamburg  
Germany

is part of the Paediatric Rheumatology International Trials Organisation  
(PRINTO, [www.printo.it](http://www.printo.it)) network as **PRINTO center DE11**.

The PRINTO center DE11 enrolled patients for the following studies as follows:

Study	No Pts Enrolled
Methotrexate (MTX) trial (medium vs high dose) in juvenile idiopathic arthritis	2
Quality of life project in the IAC project - the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ):	142
Quality of life project in juvenile idiopathic arthritis - the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ):	55
Prospective validation of JSLE/JDM disease activity and disease damage core set	5
Prospective validation of juvenile dermatomyositis disease activity and disease damage core set	2
Cyclosporine a in juvenile idiopathic arthritis. The PRCSG/PRINTO phase iv post marketing surveillance study	3

Validation of the Eular/Pres endorsed consensus criteria for the classification of childhood vasculitides	1
A randomised Phase III trial of 6 months versus 12 months withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clinical remission	15
Safety and efficacy of meloxicam in juvenile idiopathic arthritis	7
A Randomized, Double-blind Trial of Anti-TNF $\alpha$ Chimeric Monoclonal Antibody (Infliximab) in combination with Methotrexate for the Treatment of Patients with Polyarticular Juvenile Rheumatoid Arthritis	1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children with Polyarticular Juvenile Rheumatoid Arthritis	7
A Phase III, Multi-Center, Multi-National, Randomized, Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents with Active Polyarticular Juvenile Rheumatoid Arthritis (JRA)	2
Regeneron Rilonacept on systemic arthritis	13
A Multicenter, Double Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Human Anti-TNF $\alpha$ Antibody, in Pediatric Subjects with Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Methotrexate Therapy	3
A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to biologic or non biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)	5
A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis	8
A Long-term, Multi-center, Longitudinal Post-marketing, Observational Registry to Assess Long-term Safety and Effectiveness of HUMIRA (Adalimumab) in Children with Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE	41
A long-term, open-label follow-up study of Tofacitinib (cp-690,550) for treatment of juvenile idiopathic arthritis (JIA)	1

A multinational study of the EPidemiology, treatment and Outcome of Childhood Arthritis (EPOCA)	125
An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis	8
Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. A Pediatric Rheumatology InterNational Trials Organisation (PRINTO)/Pediatric Rheumatology European Society (PRES) registry	8
<b>TOTAL Pts</b>	<b>454</b>

Alberto Martini, Prof.

Nicola Ruperto, MD - MPH


